However, in other tumor types such as lung cancer and gastric cancer, MET gene amplification, without Chromosome 7 gain, was found to be a potent activator of MET pathway signaling [27–30], underscoring the complexity of MET pathway activation as an oncogenic driver across different tumor types. The gene discussed is MET; the disease is lung cancer.